<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00265733</url>
  </required_header>
  <id_info>
    <org_study_id>NCCTG-N0437</org_study_id>
    <secondary_id>NCI-2012-02683</secondary_id>
    <secondary_id>CDR0000456449</secondary_id>
    <nct_id>NCT00265733</nct_id>
  </id_info>
  <brief_title>Paclitaxel Poliglumex and Capecitabine in Treating Patients With Metastatic Breast Cancer</brief_title>
  <official_title>Phase II Trial of CT-2103 (Xyotax™) With Capecitabine as First-Line Chemotherapy for Patients With Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alliance for Clinical Trials in Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Alliance for Clinical Trials in Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as paclitaxel poliglumex and capecitabine, work&#xD;
      in different ways to stop the growth of tumor cells, either by killing the cells or by&#xD;
      stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill&#xD;
      more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving paclitaxel poliglumex together with&#xD;
      capecitabine works in treating patients with metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Assess the tumor response rate and adverse event profile in patients with metastatic,&#xD;
           HER2 negative breast cancer treated with paclitaxel poliglumex (CT-2103; Xyotax™) and&#xD;
           capecitabine.&#xD;
&#xD;
        -  Examine the distributions of disease-free progression times and survival times in these&#xD;
           patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive paclitaxel poliglumex IV (CT-2103; Xyotax™) over 10-20 minutes on day 1 and&#xD;
      oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 6 months for up to 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of confirmed tumor response (complete and partial response) as assessed by RECIST criteria</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival time</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to disease progression</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>paclitaxel + capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive paclitaxel poliglumex IV (CT-2103; Xyotax™) over 10-20 minutes on day 1 and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
After completion of study treatment, patients are followed every 6 months for up to 5 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <arm_group_label>paclitaxel + capecitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel poliglumex</intervention_name>
    <arm_group_label>paclitaxel + capecitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologic or cytologic confirmation of breast cancer with clinical evidence of&#xD;
             metastatic disease&#xD;
&#xD;
               -  No bone metastases as the only evidence of metastasis&#xD;
&#xD;
          -  Measurable disease, defined as at least one measurable lesion&#xD;
&#xD;
               -  No non-measurable disease, defined as all other lesions, including small lesions&#xD;
                  (longest diameter &lt; 2.0 cm) and truly non-measurable lesions, which include the&#xD;
                  following:&#xD;
&#xD;
                    -  Bone lesions&#xD;
&#xD;
                    -  Leptomeningeal disease&#xD;
&#xD;
                    -  Ascites&#xD;
&#xD;
                    -  Pleural/pericardial effusion&#xD;
&#xD;
                    -  Inflammatory breast disease&#xD;
&#xD;
                    -  Lymphangitis cutis/pulmonis&#xD;
&#xD;
                    -  Abdominal masses not confirmed and followed by imaging techniques&#xD;
&#xD;
                    -  Cystic lesions&#xD;
&#xD;
          -  No known brain metastasis&#xD;
&#xD;
          -  HER2 negative disease by immunohistochemistry and/or fluorescent in situ hybridization&#xD;
&#xD;
          -  Diagnostic tissue and operative and pathology reports from breast cancer diagnosis&#xD;
             and/or diagnosis of metastatic breast cancer must be available&#xD;
&#xD;
          -  Hormone receptor status&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Males or females are eligible&#xD;
&#xD;
          -  Menopausal status: not specified&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  ECOG performance status 0 or 1&#xD;
&#xD;
          -  Any serum estradiol level allowed&#xD;
&#xD;
          -  Hemoglobin &gt; 8.0 g/dL&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1500/mL&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mL&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times ULN&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times UNL&#xD;
&#xD;
          -  Calcium normal&#xD;
&#xD;
          -  Creatinine clearance ≥ 30 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Women of childbearing potential or their sexual partners must be willing to employ&#xD;
             adequate contraception (as determined by the treating physician) for the duration of&#xD;
             the study and for 30 days after treatment has ended&#xD;
&#xD;
          -  No stage III or IV invasive, non-breast malignancies in ≤ 5 years prior to&#xD;
             registration&#xD;
&#xD;
          -  No history of allergy or hypersensitivity to capecitabine, paclitaxel, or fluorouracil&#xD;
&#xD;
          -  No prior unanticipated severe reaction to fluoropyrimidine therapy&#xD;
&#xD;
          -  No known DPD deficiency&#xD;
&#xD;
          -  No known, existing uncontrolled coagulopathy&#xD;
&#xD;
          -  No uncontrolled concurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, uncontrolled hypertension, or psychiatric illness/social situations that&#xD;
             would limit compliance with study requirements&#xD;
&#xD;
          -  No lack of physical integrity of the upper gastrointestinal tract, clinically&#xD;
             significant malabsorption syndrome, or inability to take oral medication&#xD;
&#xD;
          -  No significant medical condition that would make treatment or follow-up on this&#xD;
             protocol difficult or problematic, in the opinion of the treating oncologist&#xD;
&#xD;
          -  No preexisting neuropathy &gt; grade 0&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No other concurrent cytotoxic agents, investigational drugs, immunotherapy, radiation&#xD;
             therapy or hormonal therapy&#xD;
&#xD;
          -  Capecitabine must not be administered together with antiviral drugs&#xD;
&#xD;
          -  No concurrent allopurinol, metronidazole, or sorivudine (or its chemically-related&#xD;
             analogues, such as brivudine)&#xD;
&#xD;
          -  Cimetidine must be discontinued at least 2 weeks prior to start of study treatment and&#xD;
             must be avoided while taking capecitabine&#xD;
&#xD;
          -  Patients receiving bisphosphonates are eligible for this study&#xD;
&#xD;
          -  No prior chemotherapy for metastatic disease&#xD;
&#xD;
          -  Prior anthracycline and/or taxane in the neoadjuvant or adjuvant setting allowed if&#xD;
             completed ≥ 6 months prior to registration&#xD;
&#xD;
          -  Unlimited prior hormonal therapy allowed in the neoadjuvant, adjuvant, or metastatic&#xD;
             setting&#xD;
&#xD;
          -  No HIV-positive individuals receiving combination anti-retroviral therapy&#xD;
&#xD;
          -  No major surgery, chemotherapy, or immunologic therapy ≤ 4 weeks prior to registration&#xD;
&#xD;
          -  No radiotherapy ≤ 4 weeks prior to registration, except to a non-target lesion only&#xD;
&#xD;
          -  Prior radiation to a target lesion is permitted only if there has been clear&#xD;
             progression of the lesion since radiation was completed&#xD;
&#xD;
               -  If patient receives single dose radiation for palliation, they may immediately&#xD;
                  proceed to registration without waiting 4 weeks&#xD;
&#xD;
          -  Neoadjuvant and/or adjuvant therapy must be completed &gt; 6 months prior to registration&#xD;
&#xD;
          -  No current or recent use (≤ 2 weeks prior to registration) of aspirin, anticoagulants&#xD;
             or thrombolytic agents&#xD;
&#xD;
               -  Agents to maintain patency of a vascular access device is permitted&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edith A. Perez, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Reinholz MM, Kitzmann KA, Tenner K, Hillman D, Dueck AC, Hobday TJ, Northfelt DW, Moreno-Aspitia A, Roy V, LaPlant B, Allred JB, Stella PJ, Lingle WL, Perez EA. Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, N0234/336/436/437. Clin Cancer Res. 2011 Nov 15;17(22):7183-93. doi: 10.1158/1078-0432.CCR-11-0981. Epub 2011 Oct 5.</citation>
    <PMID>21976532</PMID>
  </reference>
  <reference>
    <citation>Reinholz MM, Kitzmann KA, Hobday TJ, et al.: Cytokeratin-19 (CK19) and mammaglobin (MGB1) gene expression in circulating tumor cells (CTCs) from metastatic breast cancer patients enrolled in the NCCTG trials, N0436 and N0437. [Abstract] J Clin Oncol 27 (Suppl 15): A-11095, 2009.</citation>
  </reference>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>December 14, 2005</study_first_submitted>
  <study_first_submitted_qc>December 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2005</study_first_posted>
  <last_update_submitted>December 2, 2016</last_update_submitted>
  <last_update_submitted_qc>December 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>male breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Paclitaxel poliglumex</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

